1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is âŹ42.14 (+33.78%). The median is âŹ42.14 (+33.78%).
| Buy |
Â
4 |
| Hold |
Â
0 |
| Sell |
Â
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 300.54m | 17.30% |
| Gross profit | 257.61m | 21.45% |
| Net profit | 106.9m | 599.98% |
| EBITDA | 141.95m | 104.03% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ3.93bn |
Number of shares | 124.77m |
52-week high/low | âŹ37.58 - âŹ19.80 |
| Dividends | No |
Beta | 1.11 |
P/E ratio | 12.64 |
PEG ratio | 0.07 |
P/B ratio | -21.64 |
P/S ratio | 3.36 |
Company profile
| Name | INDIVIOR PHARMACEUTICALS INC NPV |
| CEO | Joseph J. Ciaffoni |
| Employees | 833 |
